Navigation Links
Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip
Date:1/1/2014

s, may face competition when and as they are approved and marketed. Amgen's products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products. In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen's ability to obtain or maintain patent protection for its products or product candidates. Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products. Amgen's stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates. Further, the discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen's business and results of operations.

The scientific information discussed in this news release related to Amgen's product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9,000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Br
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. NW Bios International Phase III GBM Brain Trial Is Subject Of BBC TV Report In The UK
2. Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
3. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
4. ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
5. BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
6. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
7. BioSpecifics Technologies Corp. Announces Initiation of Phase 2b Trial of CCH for Treatment of Frozen Shoulder Syndrome
8. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
9. AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data at Anesthesia Medical Conference
10. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2b Frozen Shoulder Syndrome Study of Collagenase Clostridium Histolyticum
11. Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... the United States will increase to ... will be primarily driven by expansion in the large ... energy devices will be increasingly adopted due to the ... Other key findings from Decision Resources Group,s ...
(Date:12/19/2014)... CITY, Kan. , Dec. 18, 2014 /PRNewswire/ ... PETX ), a biopharmaceutical company focused on the ... companion animals, today announced positive results from its ... innovative drug for treating pain in dogs with ... improvements in pain assessment scores that were statistically ...
(Date:12/17/2014)... 17, 2014 Revenue and earnings above ... research and development In the past 2013/14 fiscal ... two percent to EUR 4.287 billion (last year: EUR 4.190 ... percent to EUR 360 million. "Overall, 2013/14 was a successful ... Kaschke , President and CEO of Carl Zeiss AG. "Thanks ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... 19 Reportlinker.com announces that a new market research ... Production and Market of Xylose in China ... overcapacity and the global financial crisis in Q4 2008, ... small manufacturers suspended or even stopped production due to ...
... YORK, Aug. 19 Reportlinker.com announces that a ... catalogue: Advances in Large Scale ... http://www.reportlinker.com/p0265199/Advances-in-Large-Scale-BioManufacturing-and-Scale-Up-Production-2nd-ED.html A ... of Biopharmaceutical Manufacturing. This new ASM study provides ...
Cached Medicine Technology:Reportlinker Adds Production and Market of Xylose in China 2Reportlinker Adds Production and Market of Xylose in China 3Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 2Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 3
(Date:12/19/2014)... (PRWEB) December 19, 2014 After a ... performer is again returning to the stage to entertain ... husband for concert performances, and the successful tour has ... originally announced. , Visit Ticketability.com for ... newly-announced Detroit shows at fair prices. , Music fans ...
(Date:12/19/2014)... News) -- A new study suggests a possible link ... flashes and night sweats -- and higher rates of ... common during menopause, affecting about 60 percent of women. ... menopause, since they then face a higher risk of ... who exhibit moderate or severe menopausal symptoms are more ...
(Date:12/19/2014)... News) -- Prostaglandin analogue eye drops -- a common ... of vision loss in patients with the eye disease, ... David Garway-Heath, of the Moorfields Eye Hospital and UCL ... than 500 people newly diagnosed with open-angle glaucoma -- ... of the leading causes of blindness. About 45 ...
(Date:12/17/2014)... December 17, 2014 This prestigious ... practices that have made outstanding and innovative contributions ... and progression of private practice physical therapy by ... Therapy Association. , On behalf of Performance Physical ... and CEO of Performance accepted the award at ...
(Date:12/17/2014)... Now in its second year, the ... the best in senior living and home care across ... communities and agencies that have received outstanding online feedback ... nearly 100,000 providers currently listed on SeniorAdvisor.com, only 879 ... Best of 2015 Awards are located all over the ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3
... Reporter , THURSDAY, Jan. 5 (HealthDay News) -- Pediatric ... to lower the threshold for toxic lead exposure in ... and house paint, can permanently damage developing brains. ... Poisoning Prevention voted to recommend that the federal government ...
... of patients with mild-to-moderate asthma have persistently non-eosinophilic ... anti-inflammatory treatments, according to a new study. ... enrolled in nine clinical trials conducted by the ... eosinophils) was,found in only 36% of asthmatics not ...
... Mozes HealthDay Reporter , THURSDAY, Jan. 5 ... double their risk of developing a particularly advanced form ... large new European study suggests. The possible link ... (AMD), a significant cause of blindness in seniors. ...
... Proton therapy, a type of external beam radiation therapy, ... according to two new studies published in the January ... (Red Journal), the American Society for Radiation Oncology,s ... study, researchers at the University of Florida in Jacksonville, ...
... Jan. 5 (HealthDay News) -- Children and young adults ... for complications from the flu and should receive flu ... in Ohio in February 2011. Of the 130 ... young adults with neurological and neurodevelopmental conditions, 76 (58 ...
... cost paid for statins (drugs to lower cholesterol) in ... insurance is approximately 400 percent higher than comparable costs ... These findings, from the Boston University School of Medicine ... results of a comprehensive comparison of prescription drug costs ...
Cached Medicine News:Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3Health News:A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 3Health News:Proton therapy effective prostate cancer treatment 2Health News:Study finds statin costs 400 percent higher in US compared to UK 2
... The BD Vacutainer® Safety-Lok™ Blood ... deliver patient care without compromising ... Safety-Lok™ Blood Collection Set with ... with one-handed activation. This product ...
... Omni-Flex System provides the capability ... the middle of surgery while ... the incision. The system is ... stable for large patients while ...
Standard general retractor system. Fully-adjustable to maintain a low profile in any approach and any patient. Blades can be stacked on top of each other in the operative site....
... System represents the most widely accepted ... wide array of retraction components provides ... system for multi-directional exposure of the ... available for specific procedures: IMA Kit ...
Medicine Products: